Brooks Laboratories Ltd
NSE:BROOKS
Intrinsic Value
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. [ Read More ]
The intrinsic value of one
BROOKS
stock under the Base Case scenario is
38.69
INR.
Compared to the current market price of 98.95 INR,
Brooks Laboratories Ltd
is
Overvalued by 61%.
Brooks Laboratories Ltd's market capitalization is 2.6B INR.
BROOKS stock price is 98.95 INR.
BROOKS stock (38.69 INR) is 61% less than its price (98.95 INR).
BROOKS stock (18.65 INR) is 81% less than its price (98.95 INR). Open DCF Valuation
BROOKS stock (58.74 INR) is 41% less than its price (98.95 INR). Open Relative Valuation
BROOKS has downside potential of 46% compared to the average analyst price target.
Open Wall St Estimates
BROOKS's Revenue has dropped by 6% over the past 12 months.
BROOKS's ROE (Return on Equity) has increased in the last 3 years from -22% to -18%, and is approaching profitability.
BROOKS's Revenue has been falling by 3% per year for the last 3 years.
BROOKS's short-term assets (304m INR) exceed its short-term liabilties (244m INR).
BROOKS's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
BROOKS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -11% to 1%.
BROOKS has positive Gross Profit for the last twelve months.
BROOKS's ROE (Return on Equity) for the past 12 months is negative and is equal to -18%.
BROOKS has positive Operating Income for the last twelve months.
BROOKS has negative Net Income for the last twelve months.
BROOKS has negative Net Debt. This means that the company has more cash and short-term investments (10m INR) than debt (5m INR).
BROOKS has negative Free Cash Flow for the last twelve months.
BROOKS has negative three-year average ROIC (Return on Invested Capital): -14%. The company is not efficient at using invested capital to generate operating income.
BROOKS's long-term assets (1B INR) exceed its long-term liabilties (269m INR).
BROOKS's D/E (Debt to Equity) is very low and is equal to 0.01.
BROOKS has negative three-year average ROE (Return on Equity): -25%. The company is not efficient at transforming stockholders' equity into net income.
BROOKS's Altman Z-Score is very high and is equal to 9.91.
BROOKS doesn't generate enough operating income (10m INR) to safely cover interest payments on its debt (13m INR).
Valuation Backtest
Brooks Laboratories Ltd
Run backtest to discover the historical profit from buying and selling
BROOKS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Brooks Laboratories Ltd
Balance Sheet Decomposition
Brooks Laboratories Ltd
| Current Assets | 304.2m |
| Cash & Short-Term Investments | 10m |
| Receivables | 157.5m |
| Other Current Assets | 136.7m |
| Non-Current Assets | 755.8m |
| Long-Term Investments | 583.5m |
| PP&E | 140.7m |
| Intangibles | 1.4m |
| Other Non-Current Assets | 30.2m |
| Current Liabilities | 243.6m |
| Accounts Payable | 167.4m |
| Other Current Liabilities | 76.2m |
| Non-Current Liabilities | 25.1m |
| Long-Term Debt | 4.7m |
| Other Non-Current Liabilities | 20.5m |
Earnings Waterfall
Brooks Laboratories Ltd
|
Revenue
|
744.6m
INR
|
|
Cost of Revenue
|
-521m
INR
|
|
Gross Profit
|
223.6m
INR
|
|
Operating Expenses
|
-213.1m
INR
|
|
Operating Income
|
10.4m
INR
|
|
Other Expenses
|
-153.3m
INR
|
|
Net Income
|
-142.8m
INR
|
Free Cash Flow Analysis
Brooks Laboratories Ltd
BROOKS Profitability Score
Profitability Due Diligence
Brooks Laboratories Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Brooks Laboratories Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
BROOKS Solvency Score
Solvency Due Diligence
Brooks Laboratories Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
Brooks Laboratories Ltd's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BROOKS Price Targets Summary
Brooks Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for
BROOKS
is 53 INR
.
Shareholder Return
BROOKS Price
Brooks Laboratories Ltd
| Average Annual Return | 36.08% |
| Standard Deviation of Annual Returns | 69.3% |
| Max Drawdown | -74% |
| Market Capitalization | 2.6B INR |
| Shares Outstanding | 26 246 700 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Brooks Laboratories Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
BROOKS
stock under the Base Case scenario is
38.69
INR.
Compared to the current market price of 98.95 INR,
Brooks Laboratories Ltd
is
Overvalued by 61%.
You don't have any saved screeners yet
